CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled
Drug / intervention
SAVVY guidewiredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05082337
NCT05082337N/ACompleted
CompareCT.gov

The SAVVY Guidewire in Transcatheter Aortic Valve Replacement Procedures: A Feasibility Study

Institut universitaire de cardiologie et de pneumologie de Québec, University Laval·interventional·Posted Oct 18, 2021·Updated Jan 18, 2022

In Brief

A clinical study evaluating SAVVY guidewire for Aortic Valve Disease and 3 related conditions. Completed, enrolled 20 participants across 2 sites.

Detailed Summary

TAVR patients exhibiting post-procedural residual AR had higher mortality and hospitalization rates due to heart failure, with the extent of this association increasing proportionally to the severity of the regurgitation. Optimizing transcatheter valve performance by intra-procedural hemodynamic evaluation of AR and residual transvalvular gradient remains of high clinical importance.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAortic Valve Disease, Transcatheter Aortic Valve Replacement, Aortic Valve Stenosis, Hemodynamic Measurement
CountriesCanada
CollaboratorsInstitut de Cardiologie de Montréal

Timeline

N/ACompletedFinished
20222023202420252026
First PostedOct 18, 2021
Enrollment StartOct 8, 2021
Primary CompletionDec 28, 2021
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 4.7 years ago

Interventions

SAVVY guidewiredevice

The SAVVY guidewire will be used for rapid pacing runs, valve delivery and for left ventricular pressure measurements pre- and post-THV deployment